Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Tissue Repair Peptide
Evidence Grade: B (Extensive Animal Data)
BPC-157 Protocol Guide
BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It is one of the most widely researched peptides for tissue repair, tendon and ligament healing, gut mucosal protection, and angiogenesis. This protocol covers reconstitution from a 10mg vial, subcutaneous and intramuscular dosing at 250-500mcg twice daily, site-specific injection guidance, oral administration, and stacking with TB-500 for synergistic healing.
Protocol Overview
- Compound
- BPC-157 (Body Protection Compound-157)
- Category
- Tissue Repair / Cytoprotective Peptide
- Mechanism
- Upregulates growth factor expression (VEGF, EGF), promotes angiogenesis, modulates nitric oxide system, protects endothelium, and accelerates tissue granulation and remodeling
- Sequence
- 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)
- Half-Life
- ~4 hours (stable in gastric acid)
- Vial Size
- 10mg lyophilized powder
- Route
- Subcutaneous, intramuscular, or oral
- Frequency
- Twice daily (BID)
- Cycle Length
- 4-8 weeks
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Standard Healing | 250 mcg | 2x daily (AM/PM) | Subcutaneous near injury | 4-6 weeks |
| Aggressive Healing | 500 mcg | 2x daily (AM/PM) | Subcutaneous near injury | 4-8 weeks |
| Systemic / Gut | 500 mcg | 2x daily | Oral (on empty stomach) | 4-8 weeks |
| Maintenance | 250 mcg | 1x daily | Subcutaneous | 2-4 weeks |
Key principle: Inject as close to the injury site as possible for localized healing. For systemic benefits or gut healing, subcutaneous abdominal or oral administration is appropriate.
Reconstitution Instructions
Materials Needed
- BPC-157 10mg lyophilized vial
- Bacteriostatic water
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 5,000 mcg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 250 mcg | 0.05 mL | 5 units |
| 500 mcg | 0.10 mL | 10 units |
| 750 mcg | 0.15 mL | 15 units |
| 1000 mcg | 0.20 mL | 20 units |
Administration Guide
Injection Sites (Site-Specific)
- Shoulder injury: Subcutaneous over deltoid/rotator cuff area
- Knee injury: Subcutaneous around knee (medial/lateral)
- Elbow/tendon: Subcutaneous near affected tendon
- Gut healing: Subcutaneous in lower abdomen or oral
- Systemic: Abdomen (2 inches from navel)
Timing & Storage
- Timing: Morning and evening, 8-12 hours apart
- With food (injectable): Any time
- With food (oral): Empty stomach, 30 min before meals
- Storage (reconstituted): Refrigerate 2-8°C, use within 30 days
- Do not freeze reconstituted solution
Expected Timeline
Day 1-3
Initial anti-inflammatory effects. Some subjects report reduced pain and swelling at the injury site within the first few days.
Week 1-2
Noticeable reduction in inflammation and pain. Improved gut symptoms for those using for GI purposes. Enhanced blood flow to injury site via angiogenesis activation.
Week 3-4
Significant healing progress for soft tissue injuries. Tendon and ligament repair markers improve. Gut mucosal healing often well underway.
Week 5-6
Advanced tissue remodeling. Many subjects report near-complete resolution of mild to moderate injuries. Continued collagen synthesis and tissue strengthening.
Week 7-8
Protocol completion for most research objectives. Severe injuries may benefit from extended protocols or a second cycle after a 2-4 week break.
Side Effects & Monitoring
Common Side Effects
- Injection site redness or irritation (mild, transient)
- Mild dizziness or lightheadedness (uncommon)
- Nausea (rare, usually with oral dosing)
- Warmth or flushing at injection site
BPC-157 has an excellent safety profile in research literature with no significant adverse effects reported at standard doses.
Precautions
- May theoretically promote angiogenesis in existing tumors - avoid if history of cancer
- Limited human clinical trial data (primarily animal studies)
- Discontinue if unusual symptoms develop
- Not recommended during pregnancy or breastfeeding
Stacking Recommendations
Compatible Compounds
- TB-500: Synergistic healing - TB-500 for systemic + BPC-157 for localized repair
- GHK-Cu: Copper peptide for skin and tissue remodeling
- Ipamorelin: GH release to support recovery
- Glutathione: Antioxidant support during healing
- Collagen peptides: Building blocks for tissue repair
Popular Stacks
- Healing Stack: BPC-157 250mcg 2x/day + TB-500 750mcg 2x/week
- Gut Repair: BPC-157 500mcg oral 2x/day + Glutathione
- Recovery Stack: BPC-157 + Ipamorelin + GHK-Cu
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Basic Panel | CBC, CMP | Baseline, Week 4 |
| Inflammatory | CRP, ESR, IL-6 | Baseline, Week 4 (track healing) |
| Liver Function | ALT, AST, GGT | Baseline, Week 4 |
| Kidney | BUN, creatinine | Baseline |
BPC-157 has minimal systemic impact; blood work is primarily to establish baselines and track healing-related inflammatory markers.
Related Tools & Resources
📖 Encyclopedia Article
BPC-157 — Complete Research Guide
Mechanism of action, clinical evidence, pharmacokinetics, regulatory status & references
Read Article →
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Paid partnership · Learn more